Prof. Dr. Cengiz Gemici

Образование и специализация

• Медицинский факультет Университета Мармара — медицинское образование, 1983–1990
• Больница SSK Окмейданы — специализация по радиационной онкологии, 1991–1994
• Медицинский колледж парижских больниц — диплом, 1994–1995
• Университет Париж XI, медицинский факультет Париж-Юг — углублённая специализация по онкологии, 1995–1996
• Университет Париж XI, медицинский факультет Париж-Юг — углублённая специализация по медицинской онкологии, 1996–1997
• Университет Париж XI — диплом по клинической онкологии, 1995–1997

Области специализации

• Рак лёгкого
• Рак молочной железы
• Урологические опухоли
• Органосохраняющее лечение рака
• Рак пищевода, желудка и прямой кишки
• Лучевая терапия с учётом генетических данных
• Стереотаксическая лучевая терапия

Профессиональный опыт

• Больница Тенон, Париж — радиационная онкология, 1994–1995
• Больница Тенон, Париж — углублённое обучение радиационной и медицинской онкологии, 1995–1997
• Учебно-исследовательская больница Картал — радиационная онкология, 1997–2000
• Учебно-исследовательская больница Картал — руководитель обучения по радиационной онкологии, 2000–2017
• Назначение на должность доцента, 2017
• Medical Park Pendik — радиационная онкология

Профессиональные членства

• ASTRO
• ASCO

Научные публикации

• Volumetric decrease of pancreas after abdominal irradiation, it is time to consider pancreas as an organ at risk for radiotherapy planning. Gemici C, Yaprak G, Ozdemir S, Baysal T, Seseogullari OO, Ozyurt H.Radiat Oncol. 2018
• Osteoporosis development and vertebral fractures after abdominal irradiation in patients with gastric cancer. Yaprak G, Gemici C, Temizkan S, Ozdemir S, Dogan BC, Seseogullari OO. BMC Cancer. 2018
• Pre- and post-surgery treatments in rectal cancer: a long-term single-centre experience. Ozyurt H, Ozden AS, Ozgen Z, Gemici C, Yaprak G. Curr Oncol. 2017
• Radiation field size and dose determine oncologic outcome in esophageal cancer. Gemici C, Yaprak G, Batirel HF, Ilhan M, Mayadagli A. World J Surg Oncol. 2016
• Is there any role of intravenous iron for the treatment of anemia in cancer? Gemici C, Yetmen O, Yaprak G, Ozden S, Tepetam H, Ozyurt H, Mayadagli A. BMC Cancer. 2016
• Comparison of efficacy and safety of three different chemotherapy regimens delivered with concomitant radiotherapy in inoperable stage III non-small cell lung cancer patients. Ozcelik M, Korkmaz T, Odabas H, Gemici C, Ercelep O, Yuksel S, Mert AG, Surmeli H, Isik D, Aydin D, Seker M, Mayadagli A, Ozdemir P, Aliustaoglu M, Gumus M. Tumour Biol. 2016
• Whole-brain radiation therapy for brain metastases: detrimental or beneficial? Gemici C, Yaprak G. Radiat Oncol. 2015
• SRS With or Without Whole-Brain Radiation Therapy for Those With 1 to 4 Brain Metastases: In Regard to Sahgal et al. Gemici C, Yaprak G. Int J Radiat Oncol Biol Phys. 2015
• Neuroendocrine/squamous gastric collision tumor: A rare entity. Erkol B, Tilki M, Comunoğlu N, Öven Ustaalıoğlu BB, Aker F, Sürmelioğlu A, Telli F, Gemici C, Kılıçoğlu ZG, Yeşil A. Turk J Gastroenterol. 2014
• Survival in gastric cancer in relation to postoperative adjuvant therapy and determinants. Ozden S, Ozgen Z, Ozyurt H, Gemici C, Yaprak G, Tepetam H, Mayadagli A. World J Gastroenterol. 2015
• Residual tumor after neoadjuvant chemoradiation outside the radiation therapy target volume: a new prognostic factor for survival in esophageal cancer: in regard to Muijs et al. Gemici C. Int J Radiat Oncol Biol Phys. 2014
• A cross-sectional survey of the diagnosis and management of bone metastasis in breast cancer patients in Turkey. Arican A, Bozkurt T, Bozcuk H, Demirkan B, Buyukberber S, Alkis N, Sanli UA, Camci C, Yildiz M, Yucel I, Uygun K, Aslay I, Demiray M, Bese NS, Isikdogan A, Bahat Z, Gemici C, Ozdemir F, Ozdener F, Pekin B. Support Care Cancer. 2014
• Progression-free survival benefit or health-related quality-of-life advantage: which one to choose?Gemici C. J Clin Oncol. 2013
• Risk of endocrine pancreatic insufficiency in patients receiving adjuvant chemoradiation for resected gastric cancer. Gemici C, Sargin M, Uygur-Bayramicli O, Mayadagli A, Yaprak G, Dabak R, Kocak M. Radiother Oncol. 2013
• Co-existence of gastrointestinal stromal tumors with other primary neoplasms. Sevinc A, Seker M, Bilici A, Ozdemir NY, Yildiz R, Ustaalioglu BO, Kalender ME, Dane F, Karaca H, Gemici C, Gumus M, Buyukberber S. Hepatogastroenterology. 2011
• Lhermitte's sign: Review with special emphasis in oncology practice. Gemici C. Crit Rev Oncol Hematol. 2010
• Tumor lysis syndrome in solid tumors. Gemici C. J Clin Oncol. 2009
• Efficacy of iodopovidone pleurodesis and comparison of small-bore catheter versus large-bore chest tube. Caglayan B, Torun E, Turan D, Fidan A, Gemici C, Sarac G, Salepci B, Kiral N. Ann Surg Oncol. 2008
• How can we determine the role of radiotherapy in the treatment of localized aggressive non-Hodgkin's lymphoma? Gemici C, Salepci T. J Clin Oncol. 2007
• The addition of induction chemotherapy to preoperative, concurrent chemoradiotherapy improves tumor response in patients with esophageal adenocarcinoma. Gemici C. Cancer. 2007
• Tumour lysis syndrome in solid tumours. Gemici C. Clin Oncol (R Coll Radiol). 2006
• Endoscopic scoring of late gastrointestinal mucosal damage after adjuvant radiochemotherapy. Dabak R, Uygur-Bayramicli O, Gemici C, Yavuzer D, Sargin M, Yildirim M. World J Gastroenterol. 2006
• Encapsulating peritonitis and familial Mediterranean fever. Dabak R, Uygur-Bayramiçli O, Aydin DK, Dolapçioglu C, Gemici C, Erginel T, Turan C, Karadayi N. World J Gastroenterol. 2005
• Erythropoietin to treat anaemia in patients with head and neck cancer. Gemici C. Lancet. 2004
• Is liver disease an octreotide side effect? Uygur-Bayramiçli O, Gemici C. J Clin Gastroenterol. 2003
• Total-body irradiation before bone marrow transplantation for acute leukemia in first or second complete remission. Results and prognostic factors in 326 consecutive patients. Belkacémi Y, Pène F, Touboul E, Rio B, Leblond V, Gorin NC, Laugier A, Gemici C, Housset M, Ozsahin M. Strahlenther Onkol. 1998